FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 42 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 48%
  • Publisher: 63%

Federal Trade Commission Berita

Interim Report,Lina Khan,Healthcare Delivery System

The FTC released a much-anticipated interim report without taking any action. It comes as the Biden administration prepares for an uncertain election outcome...

The three largest pharmacy benefit managers are unflinching in the face of a new Federal Trade Commission interim report Tuesday outlining the intricacies of the US healthcare system — and blaming PBMs for higher drug prices.

"Much like Big Tobacco, these PBMs will continue their harmful practices until they are forced to change. Reform is urgently needed to ensure ALL PBMs prioritize patient health and affordability in their practices, and to build trust again with a more transparent and accountable healthcare system," Fields told Yahoo Finance in a statement.

The 2005 report was a look at the industry that concluded that the PBM environment was competitive — but at a time when there were still more than two dozen PBMs in the market. The iShares S&P/TSX Capped Energy Index ETF, a basket of Canadian large-cap oil and gas companies, has climbed about 17% year-to-date, outperforming the broader Canadian market.Public policy favors $7 billion fee award in Musk pay case, Tesla shareholder's lawyer says

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 47. in İD

Indonesia Berita Terbaru, Indonesia Berita utama